<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02026518</url>
  </required_header>
  <id_info>
    <org_study_id>459</org_study_id>
    <nct_id>NCT02026518</nct_id>
  </id_info>
  <brief_title>Effect of Cholecalciferol, Soy Isoflavones in Patients With Irritable Bowel Syndrome</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fasting blood specimens will be taken from the patients with IBS that have inclusion&#xD;
      criteria. First, the objectives and method of study will be explained to the patients and&#xD;
      informed consent form will be taken from them. They will be divided into 4 groups by an&#xD;
      adjusted randomized blocking and the clinical outcomes, quality of life, emotional stress&#xD;
      questionnaires will be completed before and after intervention. During 6 weeks, they will&#xD;
      receive 2 capsules of soy isoflavones per day, 50000IU vitamin D biweekly in addition to the&#xD;
      other placebo form, both of them and placebo of both. At the end, body mass index ( BMI),&#xD;
      serum TNF-Alpha, TAC, gene expression of GATA3, ROR gamma, FOXP3 in lymphocytes and gut&#xD;
      permeability will be measured. The quantity of polymorphisms of vitamin D and estrogen&#xD;
      receptors will be determined.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Clinical Outcomes (pain, flatulence, diarrhea, constipation ) at 6 weeks</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of baseline in gut permeability as efficacy at 6 weeks</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of baseline in antioxidant status as efficacy at 6 weeks</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of baseline in inflammation status as efficacy at 6 weeks</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Irritable Bowel Disease</condition>
  <arm_group>
    <arm_group_label>Soy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group Soy receiving placebo similar to 50000 IU cholecalciferol (includes MCT oil) biweekly for 6 weeks in addition to 40 milligram (2 capsules per day) soy isoflavones capsules for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Soy- Cholecalciferol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group Soy- Cholecalciferol receiving Supplement in form of 40 milligrams soy isoflavones (diadzein, genistein, glycitin) per day (2 capsules of 20 milligrams) for 6 weeks in addition to supplement of cholecalciferol (vitamin D3) biweekly for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group Placebo receiving Placebo in similar form of cholecalciferol supplement biweekly for 6 weeks in addition to 40 milligrams placebo in similar form of soy isoflavones including starch for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cholecalciferol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group Cholecalciferol receiving oral Placebo in similar form to soy isoflavones (diadzein, genistein, glycitin) supplement including starch (2 capsules per day) for 6 weeks in addition to 50000 IU cholecalciferol supplement biweekly for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Soy isoflavones</intervention_name>
    <arm_group_label>Soy</arm_group_label>
    <arm_group_label>Soy- Cholecalciferol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>cholecalciferol</intervention_name>
    <arm_group_label>Cholecalciferol</arm_group_label>
    <arm_group_label>Soy- Cholecalciferol</arm_group_label>
    <other_name>Vitamin D</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo of soy isoflavones</intervention_name>
    <arm_group_label>Cholecalciferol</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo of cholecalciferol</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Soy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. age 18-75 yrs&#xD;
&#xD;
          2. patients with Irritable Bowel Syndrome (IBS) according to ROME III criteria&#xD;
&#xD;
          3. BMI 18-25&#xD;
&#xD;
          4. a- no intestinal organic diseases b- no intestinal infection c- no history of chronic&#xD;
             gastrointestinal and colorectal diseases d- no intestinal major surgery&#xD;
&#xD;
          5. no regular use of antibiotics, anti-constipation and anti-diarrhea, immune&#xD;
             suppressors, metoclopramide, cisapride, diphenoxylate, opium and non-steroidal&#xD;
             anti-inflammatory drugs&#xD;
&#xD;
          6. no pregnancy and lactation&#xD;
&#xD;
          7. not athlete or bed rest&#xD;
&#xD;
          8. no history of breast cancer in herself or her family&#xD;
&#xD;
          9. no severe psychosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. a- use of soy isoflavones or vitamin D one year before the study b- use of soy milk or&#xD;
             soy nuts during study&#xD;
&#xD;
          2. diet changes during study&#xD;
&#xD;
          3. use of artificial sweetener 2 days before study&#xD;
&#xD;
          4. no desire to complete the study&#xD;
&#xD;
          5. adverse effect of supplement&#xD;
&#xD;
          6. pregnancy during study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gastrointestinal Clinics of Tehran University of Medical Sciences</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>December 26, 2013</study_first_submitted>
  <study_first_submitted_qc>December 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2014</study_first_posted>
  <last_update_submitted>November 17, 2014</last_update_submitted>
  <last_update_submitted_qc>November 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Mahsa Jalili</investigator_full_name>
    <investigator_title>Mrs</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

